Adalimumab-induced lupus erythematosus

Lupus

Volumn 17, Issue 7, 2008, Pages 676-678

  Martin J M ^a,b,c   Ricart, J M ^b   Alcacer J ^b   Rausell, N ^b   Arana, G ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c Hospital Clnico Universitario   (Spain)

Author keywords

Adalimumab; Drug induced lupus erythematosus; Leflunomide

Indexed keywords

ADALIMUMAB; LEFLUNOMIDE; PREDNISONE;

ADULT; ARTICLE; BLOOD CHEMISTRY; CASE REPORT; CELL DEGENERATION; DRUG WITHDRAWAL; FEMALE; HISTOLOGY; HUMAN; IMMUNOFLUORESCENCE; KERATINOCYTE; LUPUS ERYTHEMATOSUS; MALAISE; MYALGIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SKIN DEFECT; SKIN EDEMA;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SKIN;

EID: 48249153854     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307088291     Document Type: Article

References (9)

1. Haraoui, B, Keystone, E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006; 18: 96-100.
2. Van Rijthoven, AW, Bijlsma, JW, Canninga-van Dijk, M, Derksen, RH, van Roon, JA. Onset of systemic lupus erythematosus after conversion of infliximab to adalimimab treatment of rheumatoid in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford) 2006; 45: 1317-1319.
3. Scheinfeld, N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005; 4: 637-641.
4. Gensburger, D, Kawashima, M, Marotte, H, Kanitakis, J, Miossec, P. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 2005; 64: 153-155.
5. Kerr, OA, Murray, CS, Tidman, MJ. Subacute cutaneous lupus erythematosus associated with leflunamide. Clin Exp Dermatol 2004; 29: 319-320.
6. Elias, AR, Tam, CC, David-Bajar, KM. Subacute cutaneous lupus erythematosus associated with leflunomide. Cutis 2005; 76: 189-192.
7. Remer, CF, Weisman, MH, Wallace, DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001; 10: 480-483.
8. Tam, LS, Li, EK, Wong, CK, Lam, CW, Li, WC, Szeto, CC. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 2006; 65: 417-418.
9. Tam, LS, Li, EK, Wong, CK, Lam, CW, Szeto, CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004; 13: 601-604.